Ipsen Regulated Information | Investor Relations
Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  • English  EN     Français  FR     EN  arrow_down
    • English EN
    • Français FR
  •  Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Investors
  3. Regulated Information

Regulated Information

  • Regulated Information
  • Shareholders Meeting

Period

recent search

Reset

Showing: 1 – 05 of 166 Regulated Information

03 April 2026

03 April 2026

Download Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer
Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer

01 April 2026

01 April 2026

Download Ipsen announces the availability of its 2025 Universal Registration Document
Ipsen announces the availability of its 2025 Universal Registration Document

13 March 2026

13 March 2026

Download Ipsen - February 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – February 2026 – Monthly information relative to the total number of voting rights and shares composing the share capital

12 March 2026

12 March 2026

Download Ipsen appoints Michelle C. Werner as EVP, President of North America
Ipsen appoints Michelle C. Werner as EVP, President of North America

09 March 2026

09 March 2026

Download Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

Notice of Epizyme, Inc. voluntary product recall for Tazemetostat Hydrobromide Tablets (Tazverik®) Link


1 2 3 4 … 34

IPN price

€167.50

 €2.40 (1.45%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

© Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue